SK to Pursue Acquisition of French Bio CMO 'Epos케시'
[Asia Economy Reporter Hwang Yoon-joo] SK is pursuing the acquisition of 'Yposkesi,' a French contract manufacturing organization (CMO) specializing in bio raw material pharmaceuticals.
SK announced that it is in the initial stage of negotiations to acquire management rights of France's Yposkesi through its unlisted subsidiary SK Pharmteco. The scale and price of the share acquisition are under negotiation.
Yposkesi, established in 2016, is a CMO company known for its specialized technology in the field of gene and cell therapies. Completing this acquisition will mark the third global merger and acquisition (M&A) in SK's CMO business.
Hot Picks Today
If You’re Worried About Market Swings: "Steady Cash Flow Even Amid Volatility" - Experts Recommend These ETFs
- No Bacteria Detected in Arisu After 24 Hours of Repeated Drinking from a Tumbler
- "We Can't Just Let Them Be Damaged Inside"... Samsung Electronics Removes 360,000 Wafers in Preparation for Strike
- Wife in $6.7 Million Debt Took Out $3 Million in Husband's Life Insurance, Poisoned Him... US Court: "She Can Never Be Released"
- "He's Handsome, It's Such a Pity?"... Lawyer Responds to Bizarre 'Appearance Evaluation' of High School Girl Murder Suspect
Following its strategy to complete the value chain of synthetic and bio pharmaceutical CMO businesses across major bases in the US, Europe, and Asia, SK acquired the Swords plant of global pharmaceutical company BMS in Ireland in 2017, and purchased Ampac in the US in 2018.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
